Un-Audited Financial Results for the quarter and half-year ended 30th September 2025.

Revenue declinedEBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.9%Reaction day

₹133.45

prior close

₹123.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-2.8% vs market

Pharmaceuticals peers, median of 157sector+0.0%-2.9% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+2.4

15m

+2.8

30m

+2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.9-0.1-2.8+0.0-2.9

Next day

-6.3+0.5-6.8-0.1-6.2

-7.5-0.3-7.2-0.9-6.7

-8.4-0.5-7.9-1.3-7.1

-9.3-0.8-8.5-1.6-7.8

-10.1-2.3-7.8-2.3-7.8

-8.6-2.8-5.8-2.9-5.7

15d

-12.8-4.9-7.9-3.1-9.7

-10.2-4.7-5.4-4.3-5.9

-17.6-7.7-9.8-5.6-11.9

-13.0-7.8-5.2-10.3-2.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tyche Industries reported weak Q2 FY26 results. Total income fell to Rs. 1,680.93 lakhs from Rs. 2,237.86 lakhs a year ago, a ~25% YoY drop, while revenue from operations declined ~31% to Rs. 1,415.95 lakhs. Net profit after tax dropped sharply to Rs. 152.30 lakhs from Rs. 399.44 lakhs, down ~62% YoY. For H1 FY26, total income fell to Rs. 3,127.42 lakhs and PAT declined to Rs. 395.43 lakhs from Rs. 672.01 lakhs. Exports dominated sales at Rs. 2,444.25 lakhs vs. domestic sales of only Rs. 241.68 lakhs. The statutory auditor (P.S.N. Ravishanker & Associates) issued an unmodified limited review report with no qualifications.

Likely market impact

Sharp YoY declines in both revenue and profit, combined with margin compression, signal weaker operating performance and may weigh negatively on the stock. Heavy export concentration also raises concentration risk for shareholders.